Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy | Zendy

Alicia LeónCastillo | Zendy; Stephanie M. de Boer | Zendy; Melanie Powell | Zendy; Linda Mileshkin | Zendy; Helen Mackay | Zendy; Alexandra Léary | Zendy; Hans W. Nijman | Zendy; Naveena Singh | Zendy; Pamela M. Pollock | Zendy; Paul Bessette | Zendy; Anthony Fyles | Zendy; Christine Haie-Méder | Zendy; Vincent T.H.B.M. Smit | Zendy; Richard J. Edmondson | Zendy; Hein Putter | Zendy; Henry C Kitchener | Zendy; Emma J. Crosbie | Zendy; Marco de Bruyn | Zendy; Remi A. Nout | Zendy; Nanda Horeweg | Zendy; Carien L. Creutzberg | Zendy; Tjalling Bosse | Zendy

Open Access

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Author(s) -

Alicia LeónCastillo,

Stephanie M. de Boer,

Melanie Powell,

Linda Mileshkin,

Helen Mackay,

Alexandra Léary,

Hans W. Nijman,

Naveena Singh,

Pamela M. Pollock,

Paul Bessette,

Anthony Fyles,

Christine Haie-Méder,

Vincent T.H.B.M. Smit,

Richard J. Edmondson,

Hein Putter,

Henry C Kitchener,

Emma J. Crosbie,

Marco de Bruyn,

Remi A. Nout,

Nanda Horeweg,

Carien L. Creutzberg,

Tjalling Bosse

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.00549

Subject(s) - medicine , endometrial cancer , oncology , radiation therapy , adjuvant therapy , chemotherapy , cancer

The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with high-risk endometrial cancer (EC). Because The Cancer Genome Atlas defined an EC molecular classification with strong prognostic value, we investigated prognosis and impact of chemotherapy for each molecular subgroup using tissue samples from PORTEC-3 trial participants.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research